TY - JOUR
T1 - ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration
AU - Hirose, Takuo
AU - Cabrera-Socorro, Alfredo
AU - Chitayat, David
AU - Lemonnier, Thomas
AU - Féraud, Olivier
AU - Cifuentes-Diaz, Carmen
AU - Gervasi, Nicolas
AU - Mombereau, Cedric
AU - Ghosh, Tanay
AU - Stoica, Loredana
AU - d’Arc Al Bacha, Jeanne
AU - Yamada, Hiroshi
AU - Lauterbach, Marcel A.
AU - Guillon, Marc
AU - Kaneko, Kiriko
AU - Norris, Joy W.
AU - Siriwardena, Komudi
AU - Blasér, Susan
AU - Teillon, Jérémie
AU - Mendoza-Londono, Roberto
AU - Russeau, Marion
AU - Hadoux, Julien
AU - Ito, Sadayoshi
AU - Corvol, Pierre
AU - Matheus, Maria G.
AU - Holden, Kenton R.
AU - Takei, Kohji
AU - Emiliani, Valentina
AU - Bennaceur-Griscelli, Annelise
AU - Schwartz, Charles E.
AU - Nguyen, Genevieve
AU - Groszer, Matthias
N1 - Funding Information:
This work was supported in part by grants from Agence Nationale de la Recherche (ANR) (to M Groszer); Ecole des Neurosciences de Paris (to M Groszer and VE); INSERM/CNRS ATIP-AVENIR programme (to M Groszer); Fondation pour la Recherche Médicale en France (to M Groszer); l’Association “Schizo oui” (to M Groszer); Institut de France–Fondation NRJ (to M Groszer); DIM Biothérapies-Stem-Pôle (to M Groszer); Investissements d’Avenir/program (Labex Biopsy) managed by the ANR under reference ANR-11-IDEX-0004-02 (to M Groszer); a France-Stanford grant (to M Groszer); Association Vaincre les Maladies Lysosomales (to M Groszer); Fondation Lejeune (to M Groszer); Naturalia and Biologia and La Fondation du Rein (to GN); Company of Biologists (to ACS); a Grant-in-Aid for Scientific Research (23790242 and 25860156) and postdoctoral fellowship from the Japan Society for the Promotion of Science (to TH); grants ANR Investissement Avenir Infrastructure INGESTEM (to ABG); Japan Science and Technology Agency, CREST program (to KT and HY); Paris Descartes University, Collaborative Project 1199PJ05 (to MAL, M Guillon, and VE); Center for Competences in Nano-science (C’Nano) and the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7) under REA grant agreement PIEF-GA-2011-297917 (to MAL); the NIH (R01HD026202, R01NS073854); and the South Carolina Department of Disabilities and Special Needs (to CES). We thank Ricardo Dolmetsch (Stanford University, Palo Alto, California, USA) for support to establish neuronal differentiation of human iPSCs; Carsten A. Wagner (University of Zurich, Zurich, Switzerland) for the anti-ATP6V1B2 antibody; Anny Anglo, Patrick Le Griel, and Isabelle Genois for electron microscopy imaging; Christophe Tourain for custom-built electronics; Patrice Jegouzo for support with mechanical parts; Ariel de Nar-do and Alain Prochiantz (Collège de France, Paris, France) for access to microscopes; and Chika Takahashi and Takefumi Mori (Tohoku Medical and Pharmaceutical University, Sendai, Japan) for assistance with cell culture experiments. Dedicated to the memory of Ethan Francis Schwartz.
Funding Information:
This work was supported in part by grants from Agence Natio-nale de la Recherche (ANR) (to M Groszer); Ecole des Neurosciences de Paris (to M Groszer and VE); INSERM/CNRS ATIP-AVENIR programme (to M Groszer); Fondation pour la Recherche Médicale en France (to M Groszer); l’Association “Schizo oui” (to M Groszer); Institut de France–Fondation NRJ (to M Groszer); DIM Biothérapies-Stem-Pôle (to M Gro-szer); Investissements d’Avenir/program (Labex Biopsy) managed by the ANR under reference ANR-11-IDEX-0004-02 (to M Groszer); a France-Stanford grant (to M Groszer); Association Vaincre les Maladies Lysosomales (to M Groszer); Fon-dation Lejeune (to M Groszer); Naturalia and Biologia and La Fondation du Rein (to GN); Company of Biologists (to ACS); a Grant-in-Aid for Scientific Research (23790242 and 25860156) and postdoctoral fellowship from the Japan Society for the Promotion of Science (to TH); grants ANR Investissement Avenir Infrastructure INGESTEM (to ABG); Japan Science and Technology Agency, CREST program (to KT and HY); Paris Des- cartes University, Collaborative Project 1199PJ05 (to MAL, M Guillon, and VE); Center for Competences in Nano-science (C’Nano) and the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7) under REA grant agreement PIEF-GA-2011-297917 (to MAL); the NIH (R01HD026202, R01NS073854); and the South Carolina Department of Disabilities and Special Needs (to CES). We thank Ricardo Dolmetsch (Stanford University, Palo Alto, California, USA) for support to establish neuronal differentiation of human iPSCs; Carsten A. Wagner (University of Zurich, Zurich, Switzerland) for the anti-ATP6V1B2 antibody; Anny Anglo, Patrick Le Griel, and Isabelle Genois for electron microscopy imaging; Christophe Tourain for custom-built electronics; Patrice Jegouzo for support with mechanical parts; Ariel de Nardo and Alain Prochiantz (Collège de France, Paris, France) for access to microscopes; and Chika Takahashi and Takefumi Mori (Tohoku Medical and Pharmaceutical University, Sendai, Japan) for assistance with cell culture experiments. Dedicated to the memory of Ethan Francis Schwartz.
Publisher Copyright:
Copyright: © 2019, American Society for Clinical Investigation.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Vacuolar H+-ATPase–dependent (V-ATPase–dependent) functions are critical for neural proteostasis and are involved in neurodegeneration and brain tumorigenesis. We identified a patient with fulminant neurodegeneration of the developing brain carrying a de novo splice site variant in ATP6AP2 encoding an accessory protein of the V-ATPase. Functional studies of induced pluripotent stem cell–derived (iPSC-derived) neurons from this patient revealed reduced spontaneous activity and severe deficiency in lysosomal acidification and protein degradation leading to neuronal cell death. These deficiencies could be rescued by expression of full-length ATP6AP2. Conditional deletion of Atp6ap2 in developing mouse brain impaired V-ATPase–dependent functions, causing impaired neural stem cell self-renewal, premature neuronal differentiation, and apoptosis resulting in degeneration of nearly the entire cortex. In vitro studies revealed that ATP6AP2 deficiency decreases V-ATPase membrane assembly and increases endosomal-lysosomal fusion. We conclude that ATP6AP2 is a key mediator of V-ATPase–dependent signaling and protein degradation in the developing human central nervous system.
AB - Vacuolar H+-ATPase–dependent (V-ATPase–dependent) functions are critical for neural proteostasis and are involved in neurodegeneration and brain tumorigenesis. We identified a patient with fulminant neurodegeneration of the developing brain carrying a de novo splice site variant in ATP6AP2 encoding an accessory protein of the V-ATPase. Functional studies of induced pluripotent stem cell–derived (iPSC-derived) neurons from this patient revealed reduced spontaneous activity and severe deficiency in lysosomal acidification and protein degradation leading to neuronal cell death. These deficiencies could be rescued by expression of full-length ATP6AP2. Conditional deletion of Atp6ap2 in developing mouse brain impaired V-ATPase–dependent functions, causing impaired neural stem cell self-renewal, premature neuronal differentiation, and apoptosis resulting in degeneration of nearly the entire cortex. In vitro studies revealed that ATP6AP2 deficiency decreases V-ATPase membrane assembly and increases endosomal-lysosomal fusion. We conclude that ATP6AP2 is a key mediator of V-ATPase–dependent signaling and protein degradation in the developing human central nervous system.
UR - http://www.scopus.com/inward/record.url?scp=85064853420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064853420&partnerID=8YFLogxK
U2 - 10.1172/JCI79990
DO - 10.1172/JCI79990
M3 - Article
C2 - 30985297
AN - SCOPUS:85064853420
SN - 0021-9738
VL - 129
SP - 2145
EP - 2162
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 5
ER -